Clinical trial registry record

Systems Investigation of Vaccine Responses in Aging and Frailty

A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.

Plain-language guide

Five questions to ask about this record

What this is
A clinical study registration, not a result or recommendation.
Why it may matter
The registry currently reports Recruiting.
Evidence
Registered phase 2 study.
Main limitation
Registration does not prove that the intervention works, is safe, or is available to you.
What changed
Registry metadata was last updated June 12, 2025.
Where to verify
Open the primary registry below for eligibility, locations, contacts, and current status.
Registry ID
NCT05291676
Last registry update
June 12, 2025
Status
Recruiting
Phase
Phase 2
Sponsor
Yale University
Enrollment
96
Countries
United States
Match confidence
80%
Source feed
ClinicalTrials.gov
Automated source synopsis

A registered PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.

Evidence snapshot

What the source actually supports

Evidence stage
Phase 2
Study design
RANDOMIZED · PARALLEL · PREVENTION · NONE
Evidence population
Human clinical study registration
Participants
96
Population
ALL · 21 Years
Duration
2023-11-06 to 2027-04-01
Intervention
Fluzone; Fluad
Comparator
21-30 standard dose Fluad; 21-30 high dose Fluzone
Outcomes measured
Change in production of IL-6 in monocytes to assess innate immune inflammatory response — Baseline and at Day 2, 7, and…; Change in Hemagglutination inhibition titer (HAI) in response to vaccination — Baseline and Day 28; Change in transcriptomic analyses of gene expression — At Baseline, Day 2, Day 7, Day 28 and Day 70; Change in proteomic analyses — At Baseline, Day 2, Day 7, Day 28 and Day 70; Number of participants with changes in innate immune function from PBMCs and PRP as assessed using flow cytometry — At…; Number of participants with changes in B and T cell function from PBMCs as assessed using flow cytometry — At Baseline,…
Reported result
No reusable finding-level result is available in this record.

Main limitationThis is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.

Safety and approvalEligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians. Trial registration is not regulatory approval and does not establish that an intervention is available.

Source supportStructured registry protocol metadata; no finding-level conclusion is generated.

Trial stage · Phase 2A trial phase describes development stage; it does not establish a positive result.
Phase 1Phase 2Phase 3Phase 4

Registration and recruitment status do not establish safety, efficacy, or regulatory approval.

Why this record appears here · 80% topic match

The title, summary, or source keywords matched one or more topics followed by immortal.life. A higher percentage means a stronger topic match; it does not rate safety, effectiveness, or study quality.

  • Frailty · 80%Title contains controlled term: frailty. Title supplies longevity context: aging, frailty. Study type is explicitly identified as INTERVENTIONAL.

Automated source check 100% · update recency 65%. These figures help sort records; they are not medical ratings.

frailty
Open primary sourceExport JSON